/

AVCN.TO

AVICANNA INCOpen

0.1000−0.02 −13.04%CAD

Toronto · as of Oct 14, 15:05 ET · 15m delay

Open

0.1050

Prev close

0.1150

Day range

0.10000.1050

52-week range

0.09500.2980

Volume

81.50K0.96×

Mkt cap

13.44M

P/E ttm

—

Fwd P/E

-1.67

EPS ttm

-0.0300

Div yield

0.00%

Earnings

—

From 52w high

−66.44%

Price Chart

Yahoo Finance · delayed

AVCN.TOOct 14, 2026O 0.1050H 0.1050L 0.1000C 0.1000−0.0150 (−13.04%)Vol 81.50K

SMA 500.1181
SMA 2000.1480

1Y change −62.26% since Oct 10, 2025 close540 bars loadedTimes in America/TorontoDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

AVCN.TO AVICANNA INC · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −9.09%
1 month: −16.67%
3 months: −16.67%
6 months: −33.33%
Year to date: −55.56%
1 year: −62.96%

Valuation & ownership

Market cap: 13.44M
Enterprise value: 24.83M
P/E (ttm): —
Forward P/E: -1.67
PEG ratio: —
Price / book: 2.94
Price / sales (ttm): 0.53
EV / EBITDA: -7.99
EPS (ttm): -0.0300
EPS (forward): -0.0600
Beta (5y monthly): 0.35
Dividend yield: 0.00%
Payout ratio: —
Shares outstanding: 134.38M
Float: 117.65M
Short % of float: —
Short ratio (days): 0.22
Held by insiders: 21.29%
Held by institutions: 0.00%
Avg volume (3m): 84.70K
50-day average: 0.1186
200-day average: 0.1487
52-week change: −62.96%
S&P 500 52-week: +17.00%

Technicals (daily)

RSI (14): 41.3
vs 50-day SMA: −15.33%
vs 200-day SMA: −32.45%
50 / 200-day trend: ▼ 50 below 200
MACD vs signal: ▲ above
ATR (14) % of price: 7.61%
Realised vol (20d, ann.): 83.9%
From 52-week high: −66.44%
From 52-week low: +5.26%

ANR

Analyst Consensus

No analyst coverage for this instrument.

Financial Snapshot

Full statements →trailing twelve months

Revenue (ttm): 25.31M
Revenue growth (yoy): −8.40%
Earnings growth (yoy): —
Gross margin: 54.59%
Operating margin: -18.86%
Profit margin: -14.75%

DES

About AVICANNA INC

Yahoo Finance profile

Avicanna Inc., a commercial-stage biopharmaceutical company, engages in the research, development, advancement, and commercialization of evidence-based cannabinoid-based products and formulations for medical and pharmaceutical markets in Canada and internationally. It provides medical cannabis formulary products, including oral, sublingual, topical, and transdermal deliveries with various ratios of cannabinoids under the RHO Phyto brand; and indication-specific cannabinoid-based candidates to address unmet medical needs in the areas of dermatology, chronic pain, and various neurological disorders, as well as Trunerox, an indication-specific drug treatment for seizure associated with Lennox-Gastaut Syndrome and Dravet Syndrome. The company also offers active pharmaceutical ingredients comprising various cannabidiol, tetrahydrocannabinol, and cannabigerol for use in the development and production of food, cosmetics, medical, and pharmaceutical products under the Aureus Santa Marta brand. In addition, it operates MyMedi.ca, a medical cannabis care platform that offers a diverse portfolio of products and bilingual pharmacist-led patient support programs, specialty services to veterans, as well as provides educational resources to the medical community to facilitate the incorporation of medical cannabis into health care regimens; and collaborates with public and private payers for adjudication and reimbursement. The company has a research and collaboration agreement with a multinational European based pharmaceutical company to assess its proprietary SEDDS technology in combination with Collaborator's various drug delivery and pharmaceutical formats. Avicanna Inc. was incorporated in 2016 and is headquartered in Toronto, Canada.

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Employees: 112
Headquarters: Toronto, ON, Canada
Website: avicanna.com

SEAS

Seasonality · AVCN.TO

2019–2026 · monthly returns

Strongest month Dec +18.44%Weakest month Sep −14.95%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	-8.9	-12.2	-16.7	-3.3	-13.8	0.0	0.0	4.0	-19.2	-4.8			−55.6%
2025	-14.8	21.2	-3.2	-19.7	10.2	0.0	3.7	0.0	-12.5	10.2	-11.1	-6.3	−26.2%
2024	-1.4	33.3	13.0	-30.8	-27.8	53.8	-22.5	24.2	-1.3	-23.7	22.4	-14.1	−12.9%
2023	2.4	-4.8	5.0	-19.0	1.5	-10.1	-4.8	45.8	7.0	-12.0	-12.3	-1.4	−14.6%
2022	-41.0	-10.9	-20.7	20.0	-2.6	-43.4	53.5	16.7	-16.9	-3.1	6.5	24.2	−47.4%
2021	-12.2	12.2	-13.2	0.9	-5.3	0.9	0.0	0.0	-20.4	-7.0	-11.3	9.9	−40.5%
2020	-16.9	-30.3	-39.5	97.8	5.7	-14.0	-6.3	-17.3	-20.2	1.0	-16.0	56.0	−48.4%
2019								-25.5	-40.4	76.1	-58.9	60.8	−48.3%

AVCN.TO

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

AVCN.TO

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

Financial Snapshot

About AVICANNA INC

Seasonality · AVCN.TO

Insider Activity · AVCN.TO

Congress Trades · AVCN.TO

Investors Holding AVCN.TO

Investors Holding AVCN.TO

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

Financial Snapshot

About AVICANNA INC

Earnings & Dividends

News

Insider Activity · AVCN.TO

Seasonality · AVCN.TO

Congress Trades · AVCN.TO